Article
bit.bio expands senior team with four female hires
bit.bio expands senior team with four female hires in further preparation for cell therapies.
23.06.2022Content type
News
Article
Scalable, reproducible platform for reprogrammed human cells
bit.bio and Charles River Laboratories discuss the potential of precision reprogrammed human cells.
-3.png)
Article
bit.bio featured in The Sunday Telegraph
The piece talks about how bit.bio has "cracked the code" to grow human cells for a new era of regenerative medicine.
Article
bit.bio featured in European Biopharmaceutical Review
Leading experts across academia and industry share their thoughts into the challenges of in vitro cell models.
-1.png)
Article
bit.bio featured in BioSpace
The article offers 6 tips for successful pharma startups.
-1.png)
Article
bit.bio featured as case study by Cambridge Judge Business School
This case study delves into the company story, technology and vision.
Article
bit.bio featured in TechRound list of top University of Cambridge spin outs
Read the TechRound feature on Cambridge University spin-outs, including bit.bio. Learn about the origins of our opti-ox™ technolog...
Article
bit.bio CEO featured in Technology Networks
Technology Networks cover the development, benefits and applications of ioSkeletal Myocytes.
Article
bit.bio former CEO featured in TechRound
Founder and CEO Dr Mark Kotter joined the experts who have given their thoughts on what is to come for the health sector in 2022.